Home
ASC Therapeutics

ASC Therapeutics Market Share Analysis for June 2026

Industry: N/A

Domainasctherapeutics.com

Year Founded2008

Employees51 - 200

Annual Revenue--

ASC Therapeutics

ASC Therapeutics (including company regionals)

asctherapeutics.com

See more website traffic and engagement information

Total visits to ASC Therapeutics's top domains

Understand ASC Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ASC Therapeutics's top domains

Analyze ASC Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ASC Therapeutics's top domains

See how ASC Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ASC Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by ASC Therapeutics

These are the website technologies, by industry, used by ASC Therapeutics top domains

Content Management System (3)

WordPress

Mobile (3)

Meta Viewport

Widget (3)

Twemoji

Email Services (2)

G Suite

More Technologies

1

See all

News & Signals from ASC Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCharles River Laboratories International, Inc. partners with ASC Therapeutics.Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A. ASC618 is designed to deliver a shortened but optimized version of the F8 gene to liver cells (the gene is mutated in people with Hemophilia A, preventing them from producing a blood clotting protein).

NewsASC Therapeutics launches Hemophilia A Gene Therapy: Current and Next-Generation Approaches.ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic and other rare diseases announces the peer-reviewed, open-access publication of “Hemophilia A Gene Therapy: Current and Next-Generation Approaches” in Expert Opinion in Biological Therapy 1.

NewsASC Therapeutics hires Gary Potter as Senior Vice President, Global Operations.ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders announces the appointment of Gary Potter as Senior Vice President, Global Operations.